The mitapivat group will include approximately 160 participants. The placebo group will include approximately 80 participants.
The primary purpose of this study is to compare the effect of mitapivat versus placebo on transfusion burden in participants with transfusion-dependent alpha- or beta-thalassemia (TDT).